Bone metabolic biomarkers and bone mineral density in male patients with early-stage Alzheimer’s disease

Zhengping Pu,Xiaoqing Tang,Yu’e Fei,Qingmei Hou,Yong Lin,Xianyou Zha
DOI: https://doi.org/10.1007/s41999-020-00289-z
2020-01-31
European Geriatric Medicine
Abstract:To explore the correlation between bone metabolism and early-stage Alzheimer's disease in male patients. Bone metabolic biomarkers and bone mineral density (BMD) are closely correlated with the early stage of Alzheimer's disease (AD) in male patients. Measurement of bone metabolic biomarkers and BMD may provide an alternative approach for screening AD patients at the early stage. Reduced bone mineral density and altered bone metabolic markers can be used as indicators of cognitive impairments in male AD patients at an early stage. Alzheimer's disease (AD), osteoporosis, and osteopenia are the most common diseases in older individuals and share some similar pathophysiological processes of degeneration. The aim of this study is to investigate the association between bone metabolic biomarkers, bone mineral density (BMD), and early-stage AD in men. Forty-two male early-stage AD patients and 40 age-matched healthy older volunteers were enrolled. Serum calcium, osteocalcin, 1,25(OH)2D3, urine deoxypyridinoline/creatinine (DPD/Cr) ratio, urine calcium/creatinine (Ca/Cr) ratio, and BMD were measured. The correlation between early-stage AD and bone quality was evaluated. The urine DPD/Cr, urine Ca/Cr, and serum osteocalcin levels in the early-stage AD patients were significantly higher than those in the healthy control (HC) group (P
geriatrics & gerontology,gerontology
What problem does this paper attempt to address?